|
|
aluminum potassium sulfate adjuvant |
|
Vaxjo ID |
5 |
|
Vaccine Adjuvant Name |
aluminum potassium sulfate adjuvant |
|
Adjuvant VO ID |
VO_0001240
|
|
Description |
Aluminum potassium sulfate (alum) is an adjuvant that prolongs the persistence of antigen and is one of the few adjuvants approved for general human use.
((Kindt T.J. et al., 2007)) |
|
Stage of Development |
Licensed |
|
Host Species for Testing |
2 |
|
Components |
Aluminum Potassium Sulfate AlK(SO4)2 |
|
Preparation |
Precipitation with aluminum potassium sulfate: Protein adsorption to aluminum salt was carried out as described previously. The amount of hydrated aluminum potassium sulfate [AlK(S04)2. 12H20; Fisher Scientific Co., Fair Lawn, N.J.] was calculated according to the necessary amount of protein to assure a proportion of 0.8 ,ug of aluminum ion (Al3") to 100 Mg of protein. A 10% (0.21 M) solution of hydrated AlK(SO4)2 was prepared in 0.01 M phosphate- buffered saline, pH 6.2. The protein solution and the corresponding amount of 10% aluminum salt solution were mixed to a final volume of 10 ml in 0.01 M phosphate-buffered saline, pH 6.2. The pH was then adjusted to 5.0 with 1 N NaOH, and the adsorption proceeded for 2 h at room temperature with gentle stirring. The gel was then pelleted, washed twice with saline, and re-suspended in 0.1 M phosphate-buffered saline, pH 7.2. The re-suspension was made based on the adsorption of protein to the aluminum gel, the efficiency of which was over 95%. The final preparation contained 25 Mg of protein adsorbed to 0.2 Mg of Al" in 500Mul. This dose was administered to each animal (Ida et al., 1989). |
|
Function |
Aluminum-containing vaccines are prepared by the adsorption of antigens onto aluminum hydroxide or aluminum phosphate gels or by the precipitation of antigens in a solution of potassium aluminum sulfate (Heidary and Cohen, 2005). |
| Related Vaccine(s) |
|
| References |
(Kindt T.J. et al., 2007): Kindt, T.J., Goldsby, R.A, Osborne B.A.,. Antigens and Antibodies. 81. Kuby immunology. 2007. Freeman and Company, New York, NY.
Heidary and Cohen, 2005: Heidary N, Cohen DE. Hypersensitivity reactions to vaccine components. Dermatitis : contact, atopic, occupational, drug : official journal of the American Contact Dermatitis Society, North American Contact Dermatitis Group. 2005; 16(3); 115-120. [PubMed: 16242081].
Ida et al., 1989: Ida N, Sakurai S, Hosaka T, Hosoi K, Kunitomo T, Shimazu T, Maruyama T, Matsuura Y, Kohase M. Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis. Biochemical and biophysical research communications. 1989; 165(2); 728-734. [PubMed: 2480783].
|
|
